RecruitingNot Applicable

MeDex: No Perioperative Dexamethasone in Brain Metastases

United States35 participantsStarted 2026-05-01

Plain-language summary

Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. New brain tumor(s) on imaging
✓. Visceral mass(es) suspicious or confirmed for neoplasm
✓. No contraindications for craniotomy
✓. Age ≥ 18 years
✓. ECOG performance status ≤ 2 (i.e., ambulatory \> 50% of waking hours)
✓. Midline shift on MRI ≤ 10 mm
✓. Craniotomy planned to resect \>75% of the enhancing mass (surgeon's judgment)

✕. Presence of BMs not eligible for resection that are each \> 2 cm in any one dimension
✕. \>4 BMs not eligible for resection that are each 2 cm in any one dimension
✕. Treatment with laser interstitial thermal therapy (LITT)
✕. High concern for primary CNS lymphoma
✕. Diagnosis of small cell lung carcinoma
✕. Any receipt of Dex
✕. Steroid use in the past month
✕. A condition that requires steroids

Dexamethasone Rescue Need

Timeframe: 4 weeks post operative (+-) 2 weeks

NCT IDNCT07044557

SponsorUniversity of Louisville

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10

A Mistry, MD